Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1.
1. The renal actions of natriuretic peptides are dictated by the distribution of guanylyl cyclase-linked (NPRA and NPRB) and non-guanylyl cyclase-linked (NPRC) receptors. Natriuretic peptide receptors have previously been distinguished on the basis of their differential affinity for peptide fragments and analogues; however, most of the available ligands are not fully selective. We have used the specific guanylyl cyclase-linked receptor antagonist, HS-142-1, to investigate the differential distribution of natriuretic peptide receptor subtypes in the human, bovine and rat kidney. 2. Specific, high affinity 3-([125I]-iodotyrosyl)-rat-ANP-(1-28)([125I]-rANP1-28) binding sites were identified in all three species, localized to glomeruli, inner medulla, intrarenal arteries and regions in the outer medulla corresponding to vasa recta bundles. Binding sites were also identified in the smooth muscle lining of the hilar region in the bovine and rat kidney. 3. In the rat, [125I]-rANP1-28 binding was inhibited by unlabelled peptide sequences with a rank order of potency (rANP1-28 > pCNP1-22 > C-ANP4-23). The glomeruli exhibited a heterogeneous population of binding sites, C-ANP4-23 and pCNP1-22 producing a significantly better fit to a two component inhibition curve compared to the single component curve for rANP1-28. 4. Competitive inhibition experiments with the receptor selective ligands, C-ANP4-23 and HS-142-1, suggested that, like the rat, human and bovine glomeruli possessed a heterogeneous population of binding sites, whilst those in the inner medulla and intrarenal arteries of all three species represented a homogeneous population. Rat glomeruli exhibited a high proportion (>80%) of the NPRc receptor subtype whereas in human and bovine glomeruli this receptor represented less than 20% of the total population, the majority of binding sites being HS-142-1-sensitive.5. C-ANP4-23 exhibited a significantly higher inhibitory potency for binding sites in rat glomeruli compared to those in human and bovine kidney whilst HS-142-1 was significantly more potent in the rat and bovine kidney compared to man. No evidence was found to suggest the presence of a renal NPRBreceptor subtype.6. The relative density, affinity and proportion of natriuretic receptor subtypes in the kidney exhibit significant species differences. HS-142-1 may be a valuable tool in further elucidating the localization and function of these receptors, but heterogeneity between species should be considered when selecting experimental models.
Rutherford
R A
RA
Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Matsuda
Y
Y
Wilkins
M R
MR
Polak
J M
JM
Wharton
J
J
D000328:Adult; D000368:Aged; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D001345:Autoradiography; D001665:Binding Sites; D002417:Cattle; D006801:Humans; D007668:Kidney / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000494:pharmacology*; D051381:Rats; D017461:Receptors, Atrial Natriuretic Factor / Q000032:analysis* / Q000037:antagonists & inhibitors*
C072551:HS 142-1; D011134:Polysaccharides; D009320:Atrial Natriuretic Factor; D017461:Receptors, Atrial Natriuretic Factor